CD274 and neoplasm: Clinical trials investigating combinations of TGFβ inhibitors with programmed cell death protein 1(PD-1)/programmed death-ligand 1(PD-L1) inhibitors are exploring this approach, showing promising results in improving anti-tumor immunity and patient outcomes (Wrzesinski et al., 2007).